ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sintilimab

Also written as “Sintilimab”, “IBI308” and “IBI939+ Sintilimab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Colorectal Neoplasms · Esophageal Squamous Cell Carcinoma, led by 10 companies.

Drug pageSintilimab: every studyMany companies study it; this page follows only the 40 they lead. All 403 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 7, 201740 company-led studies, 13 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologicsits history only295 open or runningphase 3since May 7, 2017Oct 8, 2016Mar 25, 2030phase 3 · NCT07917468
HUTCHMEDits history only31 open or runningphase 3since Aug 16, 2022Mar 27, 2019Jan 8, 2029phase 3 · NCT06584032
Beijing Aosaikang Pharmaceuticalits history only11 open or runningphase 2since Nov 21, 2022Nov 21, 2022none ahead
Chipscreen Biosciencesits history only11 open or runningphase 3since Jun 28, 2024Jun 28, 2024May 31, 2028phase 3 · NCT06497985
CSPC Pharmaceutical Groupits history only11 open or runningphase 2since Jul 30, 2026Jul 30, 2026Sep 30, 2029phase 2 · NCT07761286
Sichuan Luzhou Buchang Biopharmaceuticalits history only11 open or runningphase 1since Jan 2, 2025Jan 2, 2025none ahead
Simcere Pharmaceutical Groupits history only10 open or runningphase 1since Jan 29, 2023Jan 29, 2023none ahead
Suzhou Zelgen Biopharmaceuticalsits history only11 open or runningphase 2since Aug 14, 2024Aug 14, 2024none ahead
TaiRx11 open or runningphase 2since Mar 31, 2026Mar 31, 2026Dec 31, 2027phase 2 · NCT07521852
TJ Biopharmaits history only11 open or runningphase 2since May 21, 2025May 21, 2025none ahead

Also a collaborator on its studies: Fortrea.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named sintilimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, IBI308
  2. Mar 31, 2026First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT07521852 · 40 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07521852

TargetBeta

PDCD1 →read by rule
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study TaiRx leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07521852Carcinoma, Hepatocellular · China2RecruitingDec 31, 202740

How it is read

Names in the registry

  • “Sintilimab”, 15 entries
  • “IBI308”, 5 entries
  • “IBI939+ Sintilimab”, 2 entries
  • “IBI110+ Sintilimab”, 2 entries
  • “fruquintinib+sintilimab”, 1 entry

Codes read as this program: IBI308.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.